Share ownership Legend Biotech Corporation

LEGN

US52490G1022

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:28:59 12/12/2025 GMT			5-day change	1st Jan Change
22.76 ^USD	-1.09%		-19.37%	-30.30%

12-10	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT
12-08	UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating	MT

Share class: Legend Biotech Corporation

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	364,566,989	360,183,848 ( 98.8 %)	0	98.8 %

Major shareholders: Legend Biotech Corporation

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 15.01 %	27,702,842	15.01 %	768 M $
Westfield Capital Management Co. LP 3.302 %	6,094,486	3.302 %	169 M $
HHLR Advisors Ltd. (Cayman Islands) 3.242 %	5,984,550	3.242 %	166 M $
Suvretta Capital Management LLC 2.069 %	3,818,009	2.069 %	106 M $
BlackRock Advisors LLC 1.94 %	3,581,535	1.94 %	99 M $
Deerfield Management Co. LP (Private Equity) 1.605 %	2,962,338	1.605 %	82 M $
Deerfield Management Co. LP 1.605 %	2,962,338	1.605 %	82 M $
Artisan Partners Holdings LP 1.38 %	2,547,952	1.38 %	71 M $
Janus Henderson Investors US LLC 1.151 %	2,125,085	1.151 %	59 M $
Braidwell LP 0.9894 %	1,826,155	0.9894 %	51 M $
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
GENSCRIPT BIOTECH CORPORATION 60.32 %	174,497,556	60.32 %	2 418 M $
Aquapoint LP 10.47 %	30,300,000	10.47 %	420 M $
Fang Liang Zhang 0.369 %	1,067,386	0.369 %	15 M $
Ying Huang 0.0741 %	214,364	0.0741 %	3 M $
Ye Wang 0.0583 %	168,642	0.0583 %	2 M $
Patrick Casey 0.0179 %	51,672	0.0179 %	715 916 $
Xiao Hui Ji 0.0178 %	51,415	0.0178 %	712 355 $
Corazon Sanders 0.0145 %	41,963	0.0145 %	581 397 $
Li Mao 0.00942 %	27,248	0.00942 %	377 521 $
Tomas Jan Heyman 0.005411 %	15,652	0.005411 %	216 858 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Genscript Biotech Corp.	94.54%
Institutional	43.84%
Other	19.63%
Individuals	0.96%
State Street Corp.	0.63%
Sumitomo Mitsui Trust Group, Inc.	0.09%
Schweizerische Nationalbank	0.09%
SEI Investments Co.	0.05%
Polar Capital Holdings Plc	0.03%
Manulife Financial Corp.	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

China	94.6%
United States	56.26%
Cayman Islands	3.41%
United Kingdom	1.22%
Individuals	0.96%
Hong Kong	0.91%
Switzerland	0.61%
Ireland	0.52%
Canada	0.33%
Luxembourg	0.3%
Japan	0.29%
Germany	0.1%
Australia	0.07%
Finland	0.06%
Sweden	0.05%
Austria	0.04%
Denmark	0.04%
Singapore	0.03%
Norway	0.03%
Spain	0.02%
South Korea	0.01%
Belgium	0.01%
Taiwan	0.01%
France	0.01%

Based on 1000 largest holdings

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Employees

2,900

Sector

Biotechnology & Medical Research

Calendar

03-17 - Q4 2025 Earnings Release (Projected)

More about the company